Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
$0.99
$0.99
$0.99
$0.99
N/A0.25N/AN/A
AEHAW
Aesther Healthcare Acquisition
$0.00
$0.01
$0.06
$0.33
N/AN/A34,287 shsN/A
AHROQ
AtheroNova
$0.00
$0.00
$0.06
N/AN/A49,080 shs150,600 shs
ONCYF
(ONCYF)
$0.74
$0.00
$0.32
$0.90
N/AN/A443,150 shs442,324 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
0.00%0.00%0.00%0.00%0.00%
AEHAW
Aesther Healthcare Acquisition
0.00%0.00%-71.52%-76.32%-94.46%
AHROQ
AtheroNova
0.00%0.00%0.00%0.00%0.00%
ONCYF
(ONCYF)
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
AHROQ
AtheroNova
N/AN/AN/AN/AN/AN/AN/AN/A
ONCYF
(ONCYF)
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
0.00
N/AN/AN/A
AEHAW
Aesther Healthcare Acquisition
0.00
N/AN/AN/A
AHROQ
AtheroNova
0.00
N/AN/AN/A
ONCYF
(ONCYF)
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/AN/A
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/A
AHROQ
AtheroNova
N/AN/AN/AN/AN/AN/A
ONCYF
(ONCYF)
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
AEHAW
Aesther Healthcare Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
AHROQ
AtheroNova
N/AN/A0.00N/AN/AN/AN/AN/AN/A
ONCYF
(ONCYF)
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/A
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/A
AHROQ
AtheroNova
N/AN/AN/AN/AN/A
ONCYF
(ONCYF)
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/A
AEHAW
Aesther Healthcare Acquisition
N/A
AHROQ
AtheroNova
N/A
ONCYF
(ONCYF)
N/A

Insider Ownership

CompanyInsider Ownership
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/A
AEHAW
Aesther Healthcare Acquisition
N/A
AHROQ
AtheroNova
34.40%
ONCYF
(ONCYF)
0.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
26N/AN/ANot Optionable
AEHAW
Aesther Healthcare Acquisition
2N/AN/ANot Optionable
AHROQ
AtheroNova
3N/AN/ANot Optionable
ONCYF
(ONCYF)
N/AN/AN/ANot Optionable

Media Sentiment Over Time

Addex Therapeutics stock logo

Addex Therapeutics OTCMKTS:ADDXF

$0.99 0.00 (0.00%)
As of 02/3/2023

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Aesther Healthcare Acquisition NASDAQ:AEHAW

$0.0026 0.00 (0.00%)
As of 07/25/2025

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

AtheroNova OTCMKTS:AHROQ

AtheroNova, Inc. operates as biotechnology company. The company engages in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. The company was founded by Giorgio Zadini and Filiberto Zadini in 1997 and is headquartered in Irvine, CA.

(ONCYF) OTCMKTS:ONCYF

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.